HTBA to Launch Leanara at Vitafoods Europe 2026 to Support Muscle and Energy in GLP-1 Users

HealthTech Bio Actives (HTBA) is set to introduce a new ingredient targeting the rapidly expanding GLP-1 companion market at Vitafoods Europe 2026, signaling continued innovation at the intersection of weight management and functional nutrition.

Launch of Leanara

The company will launch Leanara, a dual-effect ingredient formulated to support both muscle mass and energy levels in individuals using GLP-1 receptor agonists. The popularity of GLP-1 medications for weight loss continues to surge, the news release from HTBA explains.¹ “Interest in GLP‑1 weight loss therapies is already booming in the USA, and the ripple effect is reaching Europe now too, with an estimated 4.9 million British adults having recently used or expressed interest in GLP-1 medications,” states Tom D’Hoore, Chief Commercial Officer at HTBA, citing a study in BMC Medicine.²

One of the most pressing concerns tied to GLP-1 therapies is the unintended loss of lean muscle mass. “While these therapies can deliver significant reductions in body weight, research suggests that 40–60% of this loss may come from lean muscle mass if not actively managed,” states D’Hoore, referencing a study published in Diabetes, Obesity, and Metabolism.³ “This is where functional foods and supplements can play a key role, helping GLP-1 users maintain strength and vitality throughout their weight loss journey.”

According to HTBA, Leanara has been specifically developed to meet this need. The ingredient combines proprietary citrus bioflavonoids with a highly bioavailable form of vitamin B12, creating a formulation designed to support lean muscle development, reduce fatigue, and optimize metabolic function. The dual-action positioning aligns with growing consumer demand for holistic weight management solutions that go beyond simple weight reduction, HTBA explains.

At the event, HTBA will further highlight the scientific rationale behind Leanara during a presentation titled “Beyond weight loss: protect lean muscle and energy for GLP-1 users.” Presented by Teresa Pellicer, Biotechnology Manager at HTBA, the session will explore the physiological challenges associated with GLP-1 use and emphasize the role of targeted nutritional interventions in maintaining muscle integrity and metabolic health during weight loss journeys.

The launch also underscores the broader trend of “companion products” designed to complement pharmaceutical interventions. As GLP-1 usage expands, brands are increasingly looking to develop formulations that address side effects such as fatigue, reduced appetite, and nutrient deficiencies, while also supporting overall wellness.

Other HTBA Ingredients and Developments

In addition to Leanara, HTBA will showcase other ingredients from its portfolio, including MecobalActive, an active form of vitamin B12 aimed at cognitive and physical performance, and DiosVein Forte, a micronized flavonoid complex formulated for vascular health and circulation support. These ingredients will be presented in a variety of delivery formats, including powders, chewables, and gummies.

“Vitafoods Europe is an ideal platform to introduce Leanara to the industry and demonstrate how it sits within our wider portfolio of nature-led, science-backed functional health solutions,” adds D’Hoore. “Together with MecobalActive and DiosVein Forte, we’re excited to introduce Leanara to our new and existing partners at this year’s exhibition and we look forward to exploring co-creation opportunities to inspire the future of health and nutrition.” The company will be present at stand #5A14 at the event.

With more than four decades of experience in citrus flavonoids and active vitamin B12 development, HTBA has ideation centers located in Spain and in Ohio. The development of the new manufacturing plant for diosmin, known for potential for vascular support, was announced in December.

This article was created with assistance from AI. The content has been reviewed and edited by Erin McEvoy, Associate Editor. For more information on the extent and nature of AI usage, please contact us.

References

1. HTBA. Vitafoods Europe 2026: HTBA set to launch Leanara® for muscle and energy support to meet demands of growing GLP-1 companion market. Press release provided via email April 9, 2026. Accessed April 10, 2026.
2. Jackson SE, Brown J, Llewellyn, C. Mytton O, Shahab L. Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain. BMC Med. 2026;24(1). doi: 10.1186/s12916-025-04528-7
3. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl. 4):16-27. doi:10.1111/dom.15728